The epigenetic results demonstrated that the expression levels of SSX1, SSX2, and SSX3 were activated with the TSA drug in the HCT116 cells but remained unaffected in the Caco-2 cells at a similar dose, which shows that not all cancer cell types react to the same treatment and maybe display tissue specificity. The gene discussed is SSX2; the disease is cancer.